Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{618a6041f0e04db0acd3c76838d4a46f,
title = "High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer",
abstract = "Genomic screening of cancer patients for predisposing variants is traditionally based on age at onset, family history and type of cancer. Whereas the clinical guidelines have proven efficient in identifying families exhibiting classical attributes of hereditary cancer, the frequency of patients with alternative presentations is unclear. We identified and characterized germline variants in 636 patients with advanced solid cancer using whole exome sequencing. Pathogenic and likely pathogenic germline variants among 168 genes associated with hereditary cancer were considered. These variants were identified in 17.8{\%} of the patients and within a wide range of cancer types. In particular, patients with mesothelioma, ovarian cancer, cervical cancer, urothelial cancer, and cancer of unknown primary origin displayed high frequencies of pathogenic variants. Variants were predominantly found in DNA-repair pathways and about half were within genes involved in homologous recombination repair. Twenty-two BRCA1 and BRCA2 germline variants were identified in 12 different cancer types, of which 10 (45{\%}) were not previously identified in these patients based on the current clinical guidelines. Loss of heterozygosity and somatic second hits were identified in several of the affected genes, supporting possible causality for cancer development. A potential treatment target based on the pathogenic germline variant could be suggested in 25 patients (4{\%}). The study demonstrates a high frequency of pathogenic germline variants in the homologous recombination pathway in patients with advanced solid cancers. We infer that genetic screening in this group of patients may reveal high-risk families and identify patients with potential PARP inhibitor sensitive tumors.",
author = "Birgitte Bertelsen and Tuxen, {Ida Viller} and Yde, {Christina Westmose} and Migle Gabrielaite and Torp, {Mathias Husted} and Savvas Kinalis and Olga Oestrup and Kristoffer Rohrberg and Iben Spangaard and Eric Santoni-Rugiu and Karin Wadt and Morten Mau-Sorensen and Ulrik Lassen and Nielsen, {Finn Cilius}",
year = "2019",
doi = "10.1038/s41525-019-0087-6",
language = "English",
volume = "4",
pages = "13",
journal = "Genome Medicine",
issn = "1756-994X",
publisher = "BioMed Central Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer

AU - Bertelsen, Birgitte

AU - Tuxen, Ida Viller

AU - Yde, Christina Westmose

AU - Gabrielaite, Migle

AU - Torp, Mathias Husted

AU - Kinalis, Savvas

AU - Oestrup, Olga

AU - Rohrberg, Kristoffer

AU - Spangaard, Iben

AU - Santoni-Rugiu, Eric

AU - Wadt, Karin

AU - Mau-Sorensen, Morten

AU - Lassen, Ulrik

AU - Nielsen, Finn Cilius

PY - 2019

Y1 - 2019

N2 - Genomic screening of cancer patients for predisposing variants is traditionally based on age at onset, family history and type of cancer. Whereas the clinical guidelines have proven efficient in identifying families exhibiting classical attributes of hereditary cancer, the frequency of patients with alternative presentations is unclear. We identified and characterized germline variants in 636 patients with advanced solid cancer using whole exome sequencing. Pathogenic and likely pathogenic germline variants among 168 genes associated with hereditary cancer were considered. These variants were identified in 17.8% of the patients and within a wide range of cancer types. In particular, patients with mesothelioma, ovarian cancer, cervical cancer, urothelial cancer, and cancer of unknown primary origin displayed high frequencies of pathogenic variants. Variants were predominantly found in DNA-repair pathways and about half were within genes involved in homologous recombination repair. Twenty-two BRCA1 and BRCA2 germline variants were identified in 12 different cancer types, of which 10 (45%) were not previously identified in these patients based on the current clinical guidelines. Loss of heterozygosity and somatic second hits were identified in several of the affected genes, supporting possible causality for cancer development. A potential treatment target based on the pathogenic germline variant could be suggested in 25 patients (4%). The study demonstrates a high frequency of pathogenic germline variants in the homologous recombination pathway in patients with advanced solid cancers. We infer that genetic screening in this group of patients may reveal high-risk families and identify patients with potential PARP inhibitor sensitive tumors.

AB - Genomic screening of cancer patients for predisposing variants is traditionally based on age at onset, family history and type of cancer. Whereas the clinical guidelines have proven efficient in identifying families exhibiting classical attributes of hereditary cancer, the frequency of patients with alternative presentations is unclear. We identified and characterized germline variants in 636 patients with advanced solid cancer using whole exome sequencing. Pathogenic and likely pathogenic germline variants among 168 genes associated with hereditary cancer were considered. These variants were identified in 17.8% of the patients and within a wide range of cancer types. In particular, patients with mesothelioma, ovarian cancer, cervical cancer, urothelial cancer, and cancer of unknown primary origin displayed high frequencies of pathogenic variants. Variants were predominantly found in DNA-repair pathways and about half were within genes involved in homologous recombination repair. Twenty-two BRCA1 and BRCA2 germline variants were identified in 12 different cancer types, of which 10 (45%) were not previously identified in these patients based on the current clinical guidelines. Loss of heterozygosity and somatic second hits were identified in several of the affected genes, supporting possible causality for cancer development. A potential treatment target based on the pathogenic germline variant could be suggested in 25 patients (4%). The study demonstrates a high frequency of pathogenic germline variants in the homologous recombination pathway in patients with advanced solid cancers. We infer that genetic screening in this group of patients may reveal high-risk families and identify patients with potential PARP inhibitor sensitive tumors.

UR - http://www.scopus.com/inward/record.url?scp=85067833646&partnerID=8YFLogxK

U2 - 10.1038/s41525-019-0087-6

DO - 10.1038/s41525-019-0087-6

M3 - Journal article

VL - 4

SP - 13

JO - Genome Medicine

JF - Genome Medicine

SN - 1756-994X

IS - 1

M1 - 13

ER -

ID: 58596959